Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer

被引:79
|
作者
Hamaoka, T. [2 ,3 ]
Costelloe, C. M. [4 ]
Madewell, J. E. [4 ]
Liu, P. [5 ]
Berry, D. A. [5 ]
Islam, R. [1 ]
Theriault, R. L. [1 ]
Hortobagyi, G. N. [1 ]
Ueno, N. T. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[3] St Lukes Int Hosp, Tokyo, Japan
[4] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
bone diseases; breast neoplasms; diagnostic imaging; response assessment; FDG-PET; THERAPY; SCAN; TOMOGRAPHY; CARCINOMA; DIAGNOSIS; ONCOLOGY;
D O I
10.1038/sj.bjc.6605546
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: We compared the utility of a new response classification (MDA; based on computed tomography (CT), magnetic resonance imaging (MRI), plain radiography (XR), and skeletal scintigraphy (SS)) and the World Health Organisation response classification (WHO; based on XR and SS) in stratifying breast cancer patients with bone-only metastases with respect to progression-free survival (PFS), overall survival (OS), and clinical response. METHODS: We retrospectively reviewed 41 patients with bone-only metastatic breast cancer and assigned responses according to the MDA and WHO criteria. We analysed whether the MDA or WHO response classifications correlated with PFS and OS. RESULTS: With the MDA criteria, there were significant differences in PFS between patients classified as responders and those classified as nonresponders (P = 0.025), but with the WHO criteria, there were not. Neither criteria distinguished responders from nonresponders in terms of OS. MDA response criteria correlated better than WHO response criteria with clinical response assessment. CONCLUSIONS: The MDA classification is superior to the WHO classification in differentiating between responders and nonresponders among breast cancer patients with bone-only metastases. Application of the MDA classification may allow bone lesions to be considered measurable disease. Prospective study is needed to test the MDA classification among patients with bone metastasis. British Journal of Cancer (2010) 102, 651-657. doi:10.1038/sj.bjc.6605546 www.bjcancer.com Published online 26 January 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:651 / 657
页数:7
相关论文
共 50 条
  • [21] BONE-ONLY VERSUS VISCERAL-ONLY METASTATIC PATTERN IN BREAST-CANCER - ANALYSIS OF 150 PATIENTS - A GOCS STUDY
    PEREZ, JE
    MACHIAVELLI, M
    LEONE, BA
    ROMERO, A
    RABINOVICH, MG
    VALLEJO, CT
    BIANCO, A
    RODRIGUEZ, R
    CUEVAS, MA
    ALVAREZ, LA
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (04): : 294 - 298
  • [22] Correlation between Her-2 status in primary tumour and response to anastrozole in patients with metastatic breast cancer
    Drev, P.
    Golouh, R.
    Snoj, N.
    Cufer, T.
    EJC SUPPLEMENTS, 2004, 2 (03): : 178 - 178
  • [23] Proof of the Anti-Tumour Effect of Zoledronic Acid (ZA) in Naive Bone-Only Metastatic and Locally Advanced Breast Cancer: Results from the Biological Window Therapy.
    Foroni, C.
    Andreis, D.
    Maldotti, M.
    Cappelletti, M. R.
    Generali, D. G.
    CANCER RESEARCH, 2011, 71
  • [24] The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy
    K.L. Cheung
    A.J. Evans
    J.F.R. Robertson
    Breast Cancer Research and Treatment, 2001, 67 : 273 - 278
  • [25] The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy
    Cheung, KL
    Evans, AJ
    Robertson, JFR
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 67 (03) : 273 - 278
  • [26] Therapy Response Evaluation of Patients with Locally Advanced and Metastatic Breast Cancer: Comparison of Anatomic and Metabolic Criteria for Early and Accurate Response Assessment
    Gunalp, B.
    Erdogan, M.
    Ince, S.
    Balkan, E.
    Alagoz, E.
    Ayan, A.
    Arslan, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S614 - S615
  • [27] A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with "bone-only" metastatic breast cancer
    Tornyi, Ilona
    Arkosy, Peter
    Horvath, Ildiko
    Furka, Andrea
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [28] Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients
    Bouzon, Alberto
    Acea, Benigno
    Soler, Rafaela
    Iglesias, Angela
    Santiago, Paz
    Mosquera, Joaquin
    Calvo, Lourdes
    Seoane-Pillado, Teresa
    Garcia, Alejandra
    RADIOLOGY AND ONCOLOGY, 2016, 50 (01) : 73 - 79
  • [29] Oncogramme, A New Promising Method for Individualized Breast Tumour Response Testing for Cancer Treatment
    Giraud, S.
    Loum, E.
    Bessette, B.
    Fermeaux, V.
    Lautrette, C.
    ANTICANCER RESEARCH, 2011, 31 (01) : 139 - 145
  • [30] Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
    Bertho, Marion
    Fraisse, Julien
    Patsouris, Anne
    Cottu, Paul
    Arnedos, Monica
    Perol, David
    Jaffre, Anne
    Goncalves, Anthony
    Lebitasy, Marie-Paule
    D'Hondt, Veronique
    Dalenc, Florence
    Ferrero, Jean-Marc
    Levy, Christelle
    Dabakuyo, Sandrine
    Rouzier, Roman
    Penault-Llorca, Frederique
    Uwer, Lionel
    Eymard, Jean-Christophe
    Breton, Mathias
    Chevrot, Michael
    Thureau, Sebastien
    Petit, Thierry
    Simon, Gaetane
    Frenel, Jean-Sebastien
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13